Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958841 · ClinicalTrials.gov registry record · Phase 2
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT00958841 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 118 participants.
The verdict
NCT00958841, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Interventions
- DRUG pasireotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958841
The ClinicalTrials.gov registry entry for NCT00958841 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pasireotide LAR is the first listed.
NCT00958841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00958841 about?
NCT00958841 is a clinical study titled "Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin". This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
What is the current status of trial NCT00958841?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2009-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00958841?
The interventions under investigation include: pasireotide LAR (DRUG).
Who is sponsoring clinical trial NCT00958841?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.